Polaryx Therapeutics (PLYX) Change in Accured Expenses (2025)

Polaryx Therapeutics (PLYX) posted quarterly Change in Accured Expenses of -$87000.0 for Q1 2025.

Polaryx Therapeutics (PLYX) Change in Accured Expenses (2025) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Change in Accured Expenses for 1 consecutive years, with -$87000.0 the latest figure, recorded in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Accured Expenses (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	222.50 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	492.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	11.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	212.44 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	61.62 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	68.82 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Polaryx Therapeutics	99.45 Mn	87.91 Mn	-	-

Download Data